Atopic Dermatitis Market

Atopic Dermatitis Market Outlook (2022-2032)

The global atopic dermatitis market valued at US$ 5.9 Billion in 2021 and in 2022 be valued at US$ 7.3 Billion. During the 2022-2032 period of assessment, demand is expected to rise at a 24% value CAGR, likely to reach US$ 62.7 Billion by the end of the said forecast period.

Report Attributes	Details
Anticipated Base Year Value (2021)	US$ 5.9 Billion
Expected Market Value (2022)	US$ 7.3 Billion
Projected Forecast Value (2032)	US$ 62.7 Billion
Global Growth Rate (2022-2032)	24%
Growth Rate of the US (2022-2032)	CAGR 27%
Key Companies Profiled	Mylan M.V. Pfizer Inc. LEO Pharma A/S Teva Pharmaceutical Industries Ltd Sanofi Novartis AG.

Revenue of Atopic Dermatitis from 2017 to 2021 Compared to Demand Outlook for 2022 to 2032

As per the atopic dermatitis industry research by Fact.MR - a market research and competitive intelligence provider, historically, from 2017 to 2021, market value of the atopic dermatitis industry increased at around 22.7% CAGR, wherein, countries such as the U.S., U.K., China, Japan and South Korea held significant share in the global market.

The rise in cases of eczema or other skin disorder, is a primary driver of the market. Increased awareness of skin disorders, a high need for quick detection, and a growth in the frequency of skin disorders and other skin ailments are all propelling the business ahead.

The atopic dermatitis market is expected to grow in the future, as the emergence of the latest technologies in the medical sector and the introduction of innovative procedures are magnifying the demand of this market.

Owing to this, atopic dermatitis market is projected to grow at a CAGR of 24% over the coming 10 years.

Which Emerging Trends Are Driving Demand for Atopic Dermatitis?

Development of Novel Drugs to Accelerate Market Growth

Dermatological disorders are highly prevalent in various forms across the globe. According to the World Health Organization, more than 900 million people were affected by skin diseases in 2017. Out of these diseases, atopic dermatitis affects more than 300 million people globally.

Around one-fifth of the victims include children. This increased incidence of this disease is expected to leverage the growth of the atopic dermatitis market in the foreseeable future.

Other factors, such as the development of novel pipeline drugs and rising demand for new biologics and product approvals, are also expected to augment atopic dermatitis drugs demand.

The global atopic dermatitis market is project to show a stellar CAGR of 24% between 2022 and 2032, surpassing a valuation of US$ 62.7 Billion by the end of the forecast period.

Advanced Technologies in Dermatological Products

The atopic dermatitis market is expected to grow in the future, as the emergence of the latest technologies in the medical sector and the introduction of innovative procedures are magnifying the demand of this market.

In addition, the market's growth is expected to be boosted by rising acceptance and quick expansion of the novel treatment on the horizon in emerging economies throughout the forecast period. Leading companies are concentrating their efforts on the unveiling of new novel formulations as well as research and development.

For instance, in January 2021, USFDA approved AbbVie's Rinvoq and Pfizer's Cibinqo to treat moderate-to-severe atopic dermatitis, or eczema, in patients unable to respond to the previous treatments or when the use of other treatments are not recommended.

Which Market Challenges are Hampering Atopic Dermatitis Market Growth?

The high cost associated with atopic dermatitis treatment may hamper the market growth

Currently, many of developing and underdeveloped nations lack skin treatment owing to its side effects, high treatment cost, and absence of reimbursement policies in developing countries.

The treatment cost of atopic dermatitis is the main factor restraining the market growth. However, stringent regulations for product approvals and generic competition are the factors that hinder the market growth of the atopic dermatitis market globally.

Comparative View of Atopic Dermatitis Markets

Atopic Dermatitis Market :

Attributes	Atopic Dermatitis Market
Growth Factor	The rising prevalence of dermatological skin disorders developed in early childhood and more commonly found as a genetic disorder, are likely to drive the atopic dermatitis market over the course of the forecast period.
Opportunity	The development of novel pipeline drugs and rising demand for new biologics and product approvals, are also expected to augment atopic dermatitis drugs demand, and are likely to positively influence market growth over the projection period.

Atopic Dermatitis Treatment Market :

Attributes	Atopic Dermatitis Treatment Market
Growth Factor	The rise in patient base with skin disorders, and innovative procedures in accordance with the impact of macro and industry factors are some of the factors that drive the growth of the atopic dermatitis treatment market.
Opportunity	High frequency and growth in the number of patients suffering from various skin disorders, changes in climatic conditions, and the rise in disposable income, early adoption of novel medications, are major factor expected to fuel revenue growth of the market in the near future.

Mild to Moderate Atopic Dermatitis Market :

Attributes	Mild to Moderate Atopic Dermatitis Market
Growth Factor	Large patient populations and new product launches are factors projected to drive the growth of the mild-to-moderate atopic dermatitis treatment market globally.
Opportunity	Climatic changes and large pipeline products are factors which are estimated to drive growth of the global mild-to-moderate atopic dermatitis market.

Country-wise Insights

North America to Enjoy Burgeoning Growth in Atopic Dermatitis Market?

Favorable government initiatives to boost market growth in North America

North America is anticipated to maintain its regional supremacy throughout the forecast period. This is attributed to the adoption of advanced products, adequate reimbursement coverage for pharmaceutical companies and greater market penetration of new players. Also, a growing number of skin diseases across all age groups in the United States and Canada are poised to create profitable opportunities for manufacturers in the region.

The region is anticipated to grow at a dexterous CAGR of 27% during the forecast period, comprising more than half the total share of the atopic dermatitis market.

Furthermore, market development is aided by favorable government initiatives. For instance, the U.S. Food and Drug Administration (FDA) has approved its supplemental New Drug Application (sNDA) for EUCRISA® (crisaborole) ointment, 2%, extending the lower age limit from 24 months down to 3 months in children with mild-to-moderate atopic dermatitis (AD), also known as eczema.1 EUCRISA was previously approved for use in adults and children 2 years of age and older.

Why is Europe Considered a Lucrative Market for Atopic Dermatitis?

Increase in R&D activities to drive the growth of market in the region

The Europe dominates the atopic dermatitis market owing to the high prevalence of atopic dermatitis among children. Europe is the second leading market for atopic dermatitis treatment due to development activities and large research base.

Increased awareness about atopic dermatitis, favorable medical reimbursement policies and well-established healthcare facilities are projected to leverage Europe’s market share. Expected CAGR is pegged at a robust 25.5% for the forecast period.

Category-wise Insights

Based on distribution Channels which segment accounts for high revenue in the atopic dermatitis market?

Retail Pharmacies to be Lucrative Revenue Pockets of Global Atopic Dermatitis Market

By distribution channel, retail pharmacies are expected to be the most lucrative. Anticipated market share is pegged at almost four-fifth of the global atopic dermatitis market.

The growth of this segment is driven by increased number of retail pharmacy stores around the world and availability of small molecule drugs.

Easy availability of therapeutic drugs at the desired location, affordability and convenience are some other factors boosting the growth of the market. Projected CAGR for retail pharmacies amounts for 27.4% during the forecast period.

Based on drug class which segment generates a high share in atopic dermatitis market?

Biologics Drugs and PDE4 Inhibitors Account for Major Chunk of Market Share

The biologics drug segment maintained its supremacy in the global atopic dermatitis market in 2018. The segment will continue to acquire greater market share during the forecast period.

This is attributed to new product launches and increased adoption of biological drugs across several regions.

Projections indicate that the biologics segment is poised to account for a staggering CAGR of 32.4% between 2022 and 2032, surpassing a valuation of US$ 16.2 Billion.

This is followed by the growth of PDE4 Inhibitors, forecast to grow at a similar CAGR during the forecast period.

Increased affordability of treatment, extensive research and development of PDE4 Inhibitors and high adoption in key markets are factors driving growth.

Start-Ups for Atopic Dermatitis Market

Some key startups in the atopic dermatitis include Metrochem API Pvt Ltd, Arcutis Biotherapeutics among others.

• In November, 2022 - Arcutis Biotherapeutics, Inc. announced positive topline results from its INTEGUMENT-1 pivotal Phase 3 trial of roflumilast cream 0.15%, a once-daily, non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor, in adults and children six years and older with mild to moderate atopic dermatitis (AD).

Competitive Landscape

The global atopic dermatitis drugs market is dominated by six key players. These are Mylan M.V., Pfizer Inc., LEO Pharma A/S, Teva Pharmaceutical Industries Ltd, Sanofi, and Novartis AG.

Investment in research and development of new pharmaceutical drugs is the key strategy for the market expansion of the aforementioned companies. Product Development to Remain a Growth Lever for Market Players. Some of the developments in the market are

For example :

• Sanofi Genzyme manufactures the Biologics drug DUPIXNET ® which cures skin lesions and reduces itching.It does so by inhibiting the signaling of interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. These proteins are key contributors of type-2 inflammation which occurs in atopic dermatitis.
• Pfizer Inc., manufactures Eucrisa (crisaborole) which consists of PDE4 Inhibitors to treat skin ailments, particularly Eczema.The ointment targets the enzyme Phosphodiesterase-4, or PDE4, by blocking the over reactive enzymes within skin cells to prevent inflammation.

Global Atopic Dermatitis Market Segmentation

Fact.MR has studied the global atopic dermatitis market with detailed segmentation on the basis of product type, application and key regions.

• By Drug Class :

  • Corticosteroids
  • PDE4 Inhibitors
  • Biologics
  • Skin Barrier Emollients
  • CNI Immunosuppressants
  • Others

• By Distribution Channel :

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

• By Key Regions :

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa